Sugi Predict

Sugi Predict / Compounds / SCHEMBL102885

SCHEMBL102885

SCHEMBL102885

CC(C)(C)OC(=O)N1CCC=CC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ TP53 P04637 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ PSMB11 A5LHX3 1/20 0.42
▸ PSMA7 O14818 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ FOXO3 O43524 1/20 0.42
▸ MITF O75030 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ PSMB1 P20618 1/20 0.42
▸ PSMA1 P25786 1/20 0.42
▸ PSMA2 P25787 1/20 0.42
▸ PSMA3 P25788 1/20 0.42
▸ PSMA4 P25789 1/20 0.42
▸ PSMB8 P28062 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5492828 0.83 PREP (0.36) SMN1; SMN2MAPTUSP2KDM4ETHRB
SCHEMBL21039207 0.76 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1MAPTTP53LMNA
SCHEMBL21002032 0.75 KDM4E (0.41) ALDH1A1MAPTKDM4ETHRBGPR119
SCHEMBL21002061 0.75 KDM4E (0.41) ALDH1A1MAPTKDM4ETHRBGPR119
SCHEMBL21002030 0.75 KDM4E (0.41) ALDH1A1MAPTKDM4ETHRBGPR119
SCHEMBL21039217 0.75 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1MAPTTP53LMNA
SCHEMBL14801105 0.74 NR1H2 (0.47) SMN1; SMN2ALDH1A1MAPTLMNAMAPK1
SCHEMBL14112126 0.72 USP2 (0.40) SMN1; SMN2ALDH1A1MAPTLMNAMAPK1
SCHEMBL7378278 0.72 USP2 (0.46) SMN1; SMN2MAPTUSP2KDM4ETHRB
SCHEMBL25320664 0.72 ESR2 (0.40) SMN1; SMN2MAPTMAPK1USP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688144-A1 COMPOUNDS AS GLP-1R AGONISTS Terns Pharmaceuticals, Inc. (US) 2026-02-11 — — EP disclosed
US-20260015348-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-20250320217-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA INC (US) 2025-10-16 — — US disclosed
US-12410163-B2 Compounds as GLP-IR agonists TERNS PHARMACEUTICALS, INC. 2025-09-09 — — US disclosed
US-20250129085-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA INC (US) 2025-04-24 — — US disclosed
WO-2025076088-A1 LACTAMS FOR USE AS SARM1 INHIBITORS GENENTECH, INC. (US) 2025-04-10 — — WO disclosed
WO-2025066935-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2025-04-03 — — WO disclosed
EP-4482577-A1 COMPOUNDS AS GLP-1R AGONISTS Terns Pharmaceuticals, Inc. (US) 2025-01-01 — — EP disclosed
CN-119095843-A Compounds as GLP-1R agonists 拓臻制药公司 2024-12-06 — — CN disclosed
WO-2024206878-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2024-10-03 — — WO disclosed
EP-1648858-B1 METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS SIEGFRIED GENERICS INT AG (CH) 2008-07-02 — — EP disclosed
US-20060281949-A1 Method for production $g(a),$g(b)-unsaturated amide compounds SIEGFRIED GENERICS INTERNATIONAL AG (CH) 2006-12-14 — — US disclosed
EP-1648858-A1 METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS Siegfried Generics International AG (CH) 2006-04-26 — — EP disclosed
EP-1259514-B9 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN INC (US) 2005-11-09 — — EP disclosed
EP-1259514-B1 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN INC (US) 2005-06-08 — — EP disclosed
WO-2005007618-A1 METHOD FOR PRODUCTION OF $G(A),$G(B)-UNSATURATED AMIDE COMPOUNDS SIEGFRIED GENERICS INTERNATIONAL AG (CH) 2005-01-27 — — WO disclosed
EP-1259514-A2 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS Sugen, Inc. (US) 2002-11-27 — — EP disclosed
US-6465507-B2 ANTITUMOR AGENTS SUGEN, INC. 2002-10-15 — — US disclosed
US-20020042427-A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors SUGEN, INC. 2002-04-11 — — US disclosed
WO-2001064681-A2 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN, INC. (US) 2001-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015348-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR SMN1; SMN2 3129/4885ALDH1A1 3471/4885MAPT 4631/4885
US-20250129085-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 SMN1; SMN2 3075/4885ALDH1A1 3433/4885MAPT 611/4885
US-20060281949-A1 Method for production $g(a),$g(b)-unsaturated amide compounds GSTA2, GSTO1, GLB1 SMN1; SMN2 3287/4885ALDH1A1 218/4885MAPT 3147/4885
US-20020042427-A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors MAP3K20, MAP3K6, MAP3K3 SMN1; SMN2 4357/4885ALDH1A1 3908/4885MAPT 1757/4885
US-20250320217-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 SMN1; SMN2 3075/4885ALDH1A1 3433/4885MAPT 611/4885
US-12410163-B2 Compounds as GLP-IR agonists GLP1R, GIPR, GPR119 SMN1; SMN2 2678/4885ALDH1A1 3608/4885MAPT 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.